Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

Paclitaxel 2liposomal doxorubicin 1Tocotrienols 1Platinum Compounds 1EP-100 membrane-disrupting peptide 1Carboplatin 1Bevacizumab 1AC 7700 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Cancer Recurrent × Clear all
NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Asan Medical Center

Phase 2 Not yet recruiting
160 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06014528 2025-04-30

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 2 Recruiting
168 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Vejle Hospital

Phase 2 Completed
20 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed
154 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed
49 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡